Potential of allogeneic adipose-derived stem cell–hydrogel complex for treating diabetic foot ulcers

Kyung Chul Moon, Hyun Suk Suh, Ki Bum Kim, Seung Kyu Han, Ki Won Young, jinwoo lee, Mi Hyung Kim

Research output: Contribution to journalArticle

Abstract

Mesenchymal stem cells (MSCs) may hold great promise for treating diabetic wounds. However, it is difficult for a clinician to use MSCs because they have not been commercialized. Meanwhile, a new commercial drug that contains adipose-derived stem cells (ASCs) has been developed. The purpose of this study was to examine the potential of allogeneic ASC sheets for treating diabetic foot ulcers. Fifty-nine patients with diabetic foot ulcers were randomized to either the ASC treatment group (n = 30) or a control group treated with polyurethane film (n = 29). Either an allogeneic ASC sheet or polyurethane film was applied on diabetic wounds weekly. These wounds were evaluated for a maximum of 12 weeks. Complete wound closure was achieved for 73% in the treatment group and 47% in the control group at week 8. Complete wound closure was achieved for 82% in the treatment group and 53% in the control group at week 12. The Kaplan-Meier median times to complete closure were 28.5 and 63.0 days for the treatment group and the control group, respectively. There were no serious adverse events related to allogeneic ASC treatment. Thus, allogeneic ASCs might be effective and safe to treat diabetic foot ulcers.

Original languageEnglish
Pages (from-to)837-846
Number of pages10
JournalDiabetes
Volume68
Issue number4
DOIs
Publication statusPublished - 2019 Apr 1

Fingerprint

Diabetic Foot
Stem Cells
Wounds and Injuries
Control Groups
Polyurethanes
Mesenchymal Stromal Cells
Therapeutics
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Moon, K. C., Suh, H. S., Kim, K. B., Han, S. K., Young, K. W., lee, J., & Kim, M. H. (2019). Potential of allogeneic adipose-derived stem cell–hydrogel complex for treating diabetic foot ulcers. Diabetes, 68(4), 837-846. https://doi.org/10.2337/db18-0699
Moon, Kyung Chul ; Suh, Hyun Suk ; Kim, Ki Bum ; Han, Seung Kyu ; Young, Ki Won ; lee, jinwoo ; Kim, Mi Hyung. / Potential of allogeneic adipose-derived stem cell–hydrogel complex for treating diabetic foot ulcers. In: Diabetes. 2019 ; Vol. 68, No. 4. pp. 837-846.
@article{2f25097c22cb4754991c660e5cd0ebdf,
title = "Potential of allogeneic adipose-derived stem cell–hydrogel complex for treating diabetic foot ulcers",
abstract = "Mesenchymal stem cells (MSCs) may hold great promise for treating diabetic wounds. However, it is difficult for a clinician to use MSCs because they have not been commercialized. Meanwhile, a new commercial drug that contains adipose-derived stem cells (ASCs) has been developed. The purpose of this study was to examine the potential of allogeneic ASC sheets for treating diabetic foot ulcers. Fifty-nine patients with diabetic foot ulcers were randomized to either the ASC treatment group (n = 30) or a control group treated with polyurethane film (n = 29). Either an allogeneic ASC sheet or polyurethane film was applied on diabetic wounds weekly. These wounds were evaluated for a maximum of 12 weeks. Complete wound closure was achieved for 73{\%} in the treatment group and 47{\%} in the control group at week 8. Complete wound closure was achieved for 82{\%} in the treatment group and 53{\%} in the control group at week 12. The Kaplan-Meier median times to complete closure were 28.5 and 63.0 days for the treatment group and the control group, respectively. There were no serious adverse events related to allogeneic ASC treatment. Thus, allogeneic ASCs might be effective and safe to treat diabetic foot ulcers.",
author = "Moon, {Kyung Chul} and Suh, {Hyun Suk} and Kim, {Ki Bum} and Han, {Seung Kyu} and Young, {Ki Won} and jinwoo lee and Kim, {Mi Hyung}",
year = "2019",
month = "4",
day = "1",
doi = "10.2337/db18-0699",
language = "English",
volume = "68",
pages = "837--846",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "4",

}

Potential of allogeneic adipose-derived stem cell–hydrogel complex for treating diabetic foot ulcers. / Moon, Kyung Chul; Suh, Hyun Suk; Kim, Ki Bum; Han, Seung Kyu; Young, Ki Won; lee, jinwoo; Kim, Mi Hyung.

In: Diabetes, Vol. 68, No. 4, 01.04.2019, p. 837-846.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Potential of allogeneic adipose-derived stem cell–hydrogel complex for treating diabetic foot ulcers

AU - Moon, Kyung Chul

AU - Suh, Hyun Suk

AU - Kim, Ki Bum

AU - Han, Seung Kyu

AU - Young, Ki Won

AU - lee, jinwoo

AU - Kim, Mi Hyung

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Mesenchymal stem cells (MSCs) may hold great promise for treating diabetic wounds. However, it is difficult for a clinician to use MSCs because they have not been commercialized. Meanwhile, a new commercial drug that contains adipose-derived stem cells (ASCs) has been developed. The purpose of this study was to examine the potential of allogeneic ASC sheets for treating diabetic foot ulcers. Fifty-nine patients with diabetic foot ulcers were randomized to either the ASC treatment group (n = 30) or a control group treated with polyurethane film (n = 29). Either an allogeneic ASC sheet or polyurethane film was applied on diabetic wounds weekly. These wounds were evaluated for a maximum of 12 weeks. Complete wound closure was achieved for 73% in the treatment group and 47% in the control group at week 8. Complete wound closure was achieved for 82% in the treatment group and 53% in the control group at week 12. The Kaplan-Meier median times to complete closure were 28.5 and 63.0 days for the treatment group and the control group, respectively. There were no serious adverse events related to allogeneic ASC treatment. Thus, allogeneic ASCs might be effective and safe to treat diabetic foot ulcers.

AB - Mesenchymal stem cells (MSCs) may hold great promise for treating diabetic wounds. However, it is difficult for a clinician to use MSCs because they have not been commercialized. Meanwhile, a new commercial drug that contains adipose-derived stem cells (ASCs) has been developed. The purpose of this study was to examine the potential of allogeneic ASC sheets for treating diabetic foot ulcers. Fifty-nine patients with diabetic foot ulcers were randomized to either the ASC treatment group (n = 30) or a control group treated with polyurethane film (n = 29). Either an allogeneic ASC sheet or polyurethane film was applied on diabetic wounds weekly. These wounds were evaluated for a maximum of 12 weeks. Complete wound closure was achieved for 73% in the treatment group and 47% in the control group at week 8. Complete wound closure was achieved for 82% in the treatment group and 53% in the control group at week 12. The Kaplan-Meier median times to complete closure were 28.5 and 63.0 days for the treatment group and the control group, respectively. There were no serious adverse events related to allogeneic ASC treatment. Thus, allogeneic ASCs might be effective and safe to treat diabetic foot ulcers.

UR - http://www.scopus.com/inward/record.url?scp=85063638847&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063638847&partnerID=8YFLogxK

U2 - 10.2337/db18-0699

DO - 10.2337/db18-0699

M3 - Article

VL - 68

SP - 837

EP - 846

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 4

ER -